Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Kv7 (KCNQ) channel modulators and neuropathic pain.

× No keyword cloud information.

18 in total

1. Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener.

Authors: Haibo Yu; Meng Wu; Steven D Townsend; Beiyan Zou; Shunyou Long; J Scott Daniels; Owen B McManus; Min Li; Craig W Lindsley; Corey R Hopkins
Journal: ACS Chem Neurosci Date: 2011-10-19 Impact factor: 4.418

Review 2. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors: Heike Wulff; Boris S Zhorov
Journal: Chem Rev Date: 2008-05 Impact factor: 60.622

3. N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

Authors: George Amato; Rosemarie Roeloffs; Greg C Rigdon; Brett Antonio; Theresa Mersch; Grant McNaughton-Smith; Alan D Wickenden; Paul Fritch; Mark J Suto
Journal: ACS Med Chem Lett Date: 2011-03-31 Impact factor: 4.345

4. Modulation of K(v)7 potassium channels by a novel opener pyrazolo[1,5-a]pyrimidin-7(4H)-one compound QO-58.

Authors: F Zhang; Y Mi; J L Qi; J W Li; M Si; B C Guan; X N Du; H L An; H L Zhang
Journal: Br J Pharmacol Date: 2013-02 Impact factor: 8.739

5. Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery.

Authors: Bharath K Mani; Lioubov I Brueggemann; Leanne L Cribbs; Kenneth L Byron
Journal: Br J Pharmacol Date: 2011-09 Impact factor: 8.739

Review 6. Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration.

Authors: Niyathi Hegde Shah; Elias Aizenman
Journal: Transl Stroke Res Date: 2013-11-19 Impact factor: 6.829

Review 7. Voltage-gated potassium channels as therapeutic targets.

Authors: Heike Wulff; Neil A Castle; Luis A Pardo
Journal: Nat Rev Drug Discov Date: 2009-12 Impact factor: 84.694

8. Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance.

Authors: Alexander R Mackie; Lioubov I Brueggemann; Kyle K Henderson; Aaron J Shiels; Leanne L Cribbs; Karie E Scrogin; Kenneth L Byron
Journal: J Pharmacol Exp Ther Date: 2008-02-13 Impact factor: 4.030

9. Enhancing m currents: a way out for neuropathic pain?

Authors: Ivan Rivera-Arconada; Carolina Roza; Jose A Lopez-Garcia
Journal: Front Mol Neurosci Date: 2009-08-04 Impact factor: 5.639

10. Molecular basis for ligand activation of the human KCNQ2 channel.

Authors: Xiaoxiao Li; Qiansen Zhang; Peipei Guo; Jie Fu; Lianghe Mei; Dashuai Lv; Jiangqin Wang; Dongwu Lai; Sheng Ye; Huaiyu Yang; Jiangtao Guo
Journal: Cell Res Date: 2020-09-03 Impact factor: 25.617